ClinicalTrials.gg
Active, not recruitingNCT04806854OraGrowtH212Updated Oct 4, 2023

PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)

A Phase 2 interventional study of LUM-201 in Growth Hormone Deficiency, sponsored by Lumos Pharma. Active, not recruiting at 1 site in Chile. Open to participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2023-10-04.

Sponsored by Lumos Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
4 Years to 9 Years
Sex
All
01

Study summary

The goals of this single site trial are to study the pharmacokinetics (PK) and pharmacodynamics of LUM-201 and effects of LUM-201 administration on growth hormone release over time in children with idiopathic pediatric growth hormone deficiency (PGHD).

Read the detailed description

This trial will have a single screening visit to assess if subjects are eligible to start study therapy. Once subjects have completed screening, and if they are determined to be eligible, they will return to the clinic for a 12-hour pulsatility study. On Day Two of the trial, subjects will be randomized to receive one of two oral daily doses of LUM-201 and PK samples will be collected. All subjects will have an equal chance of being placed in either of the two groups.

The trial consists of treatment until subjects achieve near adult height. After screening, subjects will return to the clinic monthly for the first 6 visits and every three months thereafter. At most clinic visits, subjects will have a physical exam, blood and urine collections. At the Month 6 visit subjects will repeat the 12-hour pulsatility and PK studies.

02

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

Keywords

  • GHD, PGHD, LUM-201, growth hormone secretagogue, height, catch-up growth, pulsatility, pharmacokinetics, pharmacodynamics, PK, PD, idiopathic
03

In context

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

This study's planned enrollment of 24 is below the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.

Browse Dwarfism, Pituitary studies →

Lead sponsor

Lumos Pharma is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a chronological age ≥ 4.0 years and ≤ 10.0 years for girls and ≤ 12.0 years for boys.
  • Have a minimum body weight of 16 kg at the time of screening.
  • Have a bone age examination at screening or within the 6 months prior to screening that is delayed with respect to chronological age. Bone age should be based on the apparent BA of the proximal and distal phalanges, as opposed to the metacarpals, carpals and distal forearm. A central BA reader will make the final determination on BA eligibility.
  • Have HT-SDS ≤ -2.0 or a HT-SDS ≥ 2 SD below mean parental HT-SDS. If the other data (slow HV, low IGF-1, peak GH \< 10, and 6-month BA delay) are all consistent with idiopathic GHD, the subject may be enrolled with a height SDS > -2.0 after consultation with the MMs.
  • Have an accurate baseline height velocity ≤ 5.5 cm/year based on at least 6-months of growth, if available
  • Within the past 6 months have a maximal GH response > 3 and \< 10 ng/mL from at least one prior GH stimulation test within the past 6 months
  • Have prepubertal status as evidenced by Tanner Stage I breast development in girls and testicular volume \< 4.0 mL in boys.
  • Have an arm span to height ratio > 96.5%
  • In girls, have genetic testing results to rule out Turner syndrome. If SHOX genetic testing results are available, they need to be negative.
  • Have normal thyroid function. Subjects diagnosed with hypothyroidism must have documented successful treatment for at least 30 days prior to the Baseline visit.

Exclusion criteria

Exclusion Criteria:

  • Any medical or genetic condition which, in the opinion of the PI or Medical Monitor (MM), can be an independent cause of short stature and/or limit the response to exogenous growth factor treatment (e.g., diabetes, , idiopathic short stature (ISS), SHOX-deficiency, skeletal dysplasia, constitutional growth delay, SGA, other).
  • A medical or genetic condition that, in the opinion of the PI and/or MM, adds unwarranted risk to use of LUM-201 (e.g., scoliosis).
  • Use of any medication that, in the opinion of the PI and/or MM, can independently cause short stature or limit the response to exogenous growth factors (e.g., ).
  • Evidence or history of an intracranial mass (e.g., pituitary tumor, craniopharyngioma).
  • Prior treatment with growth factors including, but not limited to, GH, IGF-1, and GH secretagogues. (These may be used for limited times as a diagnostic test.)
  • Suspicion of absence of pituitary function as evidenced by a maximal stimulated GH ≤ 3 ng/mL or pituitary hormone deficiencies beyond GH and thyroid function or a diagnosis of Organic PGHD.
  • At birth, gestational age \< 36.0 weeks.
  • Participation in any therapeutic trial of drug(s) within the prior 6 months.
  • History of spinal, cranial or total body irradiation.
  • Recent commencement of non-stimulant therapy to treat attention deficit hyperactivity disorder (ADHD).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    LUM-201 (1.6 mg/kg/day)

    Drug: LUM-201

  • Experimental
    LUM-201 (3.2 mg/kg/day)

    Drug: LUM-201

Interventions

  • Administered orally once daily

06

What researchers measure

Primary outcomes

  1. Evaluation of Augmented Growth Hormone (GH) Pulsatility

    12-hour mean GH concentration

    Time frame: Day 1 to Month 6

  2. Pharmacokinetics of LUM-201 and M8

    Plasma concentrations (Cmax/Steady State)

    Time frame: Day 1 to Month 6

Secondary outcomes

  1. Incidence of adverse events in children with idiopathic GHD

    Number of events

    Time frame: up to 8 years

  2. Height standard deviation score (SDS)

    Change in HT-SDS from Baseline to Month 6 and Month 12

    Time frame: Day 1 to Month 12

07

Study locations

1 site
  • Institute of Maternal and Child Research, University of Chile
    Santiago, Chile
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Apr 2030, 105 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2021
First posted
Mar 19, 2021
StartActual
Jul 14, 2021
Primary completionEst.
Apr 2030
CompletionEst.
Jul 2030
Last update
Oct 4, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04806854
Lead sponsor
Lumos Pharma
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Jul 14, 2021
Primary completion
Apr 2030 (estimated)
Completion
Jul 2030 (estimated)
Last update
Oct 4, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibutamoren

Start the discussion